Enamel matrix protein compositions for modulating immune response
CA 2459773 A1 · Owner: Biora Ab · Inventors: Gestrelius, Stina; Lyngstadaas, Stale Petter
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to the use of a preparation of an active enamel matrix substance, such as an amelogenin for the manufacture of a , pharmaceutical composition for modulating an immune response. The composition can be used in preventing and/or treating a condition or disease in a mammal that is characterised by said mammal presenting an imbalance in its native immune response to an internal and/or external stimuli i.e. wherein at least , a part of said mammal's immune system is stimulated non-discriminatingly reacts hypersensitivity to said immunogen or fails to react to said stimuli. , Said condition can typically either be systematic or local such as a systemic , and/or …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 6, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 6, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 6, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.